Search Menu
HIV Treatment Bulletin

Glasgow 2026: Pipeline compounds for HIV treatment and prevention

HIV Drug Therapy Glasgow 2026.
Simon Collins, HIV i-Base

A comprehensive overview of more than 20 new HIV drugs and formulations was presented by Trip Gulick from Weill Cornell Medical College and the ACTG in a plenary lecture on new drugs and treatment strategies. [1]

This shows a surprisingly strong pipeline with new compounds in most classes that could potentially offer a range of new long-acting combinations that are more tolerable and require fewer doses.

However, drug companies generally have a focus on developing their own in-house long-acting combinations rather than working collaboratively, other than on one of the once-weekly oral formulations.

These once-weekly options are not only closest to market but might offer the simplest positive impact on quality of life for people currently on daily oral ART.

The most exciting developments for PrEP included weekly oral lenacapavir and monthly oral alimatravir.

The report below is supplemented with additional results from more than 20 additional oral and poster presentations at Glasgow 2026.

Cabotegravir: 4-monthly injections

A new ultra long-acting formulation of cabotegravir (CAB-ULA) from ViiV Healthcare extends injections from 600 mg every two months to 1600 mg every four months. CAB-ULA is already in phase 3 research as a switch study called CUATRO in people currently suppressed on oral ART who are randomised to either CAB/RPV-LA or CAB/RPV-ULA. [2]

Phase 1 and 2 PrEP studies that switch people from 2-monthly injections to the 4-monthly formulation or who start with 4-monthly PrEP (EXTEND4M) are also enrolled and ongoing.

CAB/RPV-LA with detectable viral load

There is also increasing data supporting the use of the two-monthly formulations of CAB/RPV-LA in people with detectable viral load, which is currently only recommended in guidelines in selected cases.

These include a meta-analysis reporting 87% viral efficacy in 244 participants in 2025 and the randomised A5359 LATITUDE study that reported viral failure in 249 participants (at 48 weeks) in 23% vs 41% in participants using injectable vs oral ART respectively. [4]

The randomised SUPLA study in 45 participants with median viral load of 35,000 copies/mL reported viral suppression at week 24 in 76% vs 40% injectable vs oral ART. [5]

The CROWN study in 332 people with viral load >1000 copies/mL randomised 3:1 is still ongoing but has reported top-level results of meeting the primary endpoint of injectable CAB/RPV-LA being superior to oral ART. Full results expected shortly. [6]

Cabotegravir plus lenacapavir

Small studies have also reported using 2-monthly CAB-LA with 6-monthly injectable lenacapavir (LEN) especially when RPV-LA is not appropriate due to NNRTI resistance or access issues. The talk referred to 94% suppression in 32/34 participants at week 8. [7]

However, a more recent retrospective study from the same group included 24 people with median baseline viral load of 14,000 copies/mL (range: 200 to 1.2 million). All participants achieved viral suppression within 13 weeks and none have rebounded after a median of 100 weeks. [8]

Further studies are planned, including two new ACTG studies (A5431 and A5433), though are not yet enrolling and other studies in Africa have stalled because neither Gilead nor ViiV have so far agreed to sell their drugs to enable the research to start.

Lenacapavir (LEN) PrEP: generic & annual PrEP and  oral ART

The currently approved formulation of injectable lenacapavir PrEP is manufactured by Gilead for use in high- and many middle-income countries with a list price of $28,000 per year. After an initial loading oral dose, the 927 mg dose is given as 2 x 1.5 cc subcutaneous injections every 6 months.

Importantly, the FDA just approved the first generic version of LEN for use in 120 selected low- and middle-income countries, with a recommended price of $40 a year.

Gilead is also developing a 12-monthly formulation for PrEP, and the phase 3 PURPOSE-365 study, using a 3000 mg dose given as 2 x 3 cc intramuscular injections is already enrolled, with a primary PK endpoint at week 52. [9]

Earlier this year, a weekly oral formulation of LEN, used as a bridging dose if injections are delayed, was also submitted to the US FDA as weekly oral PrEP, with an expected decision by February 2027.

Lenacapavir with detectable viral load

Earlier this year, the phase 2 CALIBRATE study reported good viral suppression from using 6-monthly injectable lenacapavir in combination with daily oral F/TAF as first-line ART and included an arm using F/TAF with daily oral LEN. [10]

However, Gilead is not continuing with further treatment-naive studies with injectable LEN.

Bictegravir/lenacapavir (BIC/LEN) once-daily oral

In August 2026, the FDA approval of daily oral 50 mg lenacapavir coformulated with oral 75 mg bictegravir (BIC/LEN) as a switch option to simplify people on complex ART reported impressive viral suppression in the ARTISTRY 1 and 2 studies. [11, 12]

Two posters at Glasgow 2026 included further details from these studies.  One poster reported a low impact of baseline resistance on outcomes and emergence of drug resistance on treatment in only 1/133 participants with detectable viral load. [13]

The second poster reported on viral rebound events >200 copies/mL in 39 participants in a combined analysis from both studies, of whom 32/39 resuppressed <50 copies/mL without changing treatment. Results on the remaining 7/39 are difficult to find in the poster. [14]

Oral lenacapavir is also being developed as part of weekly ART, including with islatravir (see below).

Islatravir/doravirine (ISL/DOR) daily oral

The new once-daily oral combination of islatravir/doravirine (ISL/DOR) (0.25 mg/300 mg) was approved by the US FDA in April 2026, based on two phase 3 switch studies showing non-inferiority to controls. It is marketed by Merck/MSD with the brand name IDVYNSO.

Three posters at Glasgow 2026 included new data on this combination. [15, 16, 17]

Once-weekly oral ART

Islatravir/lenacapavir once-weekly

There is also considerable interest in the once-weekly formulation of islatravir/lenacapavir (2 mg/300 mg) currently in the phase 3 ISLEND-1 and -2 studies with >90% viral suppression at week 52 which was non-inferior to daily oral ART controls arms. Although the US FDA hasn’t released a timeline for approval, Merck/MSD say they plan to launch in 2027.

Four posters at Glasgow 2026 reported consistent positive benefits of once-weekly ISL/LEN, including emotional and logistical QoL, easier treatment, and reduced daily reminder of HIV status. [18, 19, 20, 21]

Oral ulonivirine (ULO, MK-8507) once-weekly

Ulonivirine (ULO) is an oral NNRTI similar to doravirine and is being studied in a once-weekly 200 mg coformulation with 2 mg islatravir. Results from a phase 2b switch study reported at IAS 2026 included 95% remaining suppressed <50 copies/mL at 24 weeks vs 98% in the B/F/TAF control arm. [22]

There were two posters on ULO at Glasgow 2026, one showing that dosing can cover a window period of a week if one dose is missed and another on PK. [23, 24]

Large randomised phase 3 trials include two switch studies (Symphoria 1 and 2) and one as first-line ART in treatment-naive participants (Symphoria 3) which are already recruiting.

Other NNRTIs

Other NNRTIs in development include bavtavirine (GS-5894) currently in phase 1 and a 4-monthly formulation of injectable rilpivirine (RPV-ULA) which was included as an oral presentation at Glasgow 2026. [25].

Alimatravir (MK-8527): once-monthly oral PrEP

Alimatravir is a once-monthly oral NRTTI being developed by Merck/MSD that is similar to islatravir but will only be used as PrEP.

Although still in ongoing phase 3 studies, without efficacy data yet, licenses for distribution in 129 selected low- and middle-income countries have already been arranged with generic companies, and it should be significantly cheaper to manufacture and distribute than injectable PrEP.

Two posters at Glasgow report demographics of the large, randomised, international double-blind, placebo-controlled EXPRESSIVE 10 and 11 studies that use FTC/TDF as the control arm. Both studies remain double-blinded for two years for the primary efficacy endpoint and both are now fully enrolled. [26, 27]

Other 6-monthly injectable INSTIs

VH-184 is a third-generation integrase inhibitor from ViiV with a stronger resistance profile that is being developed in oral daily and 6-monthly injectable formulations. The phase 2b INNOVATE study using oral VH-184 + TDF/FTC in 186 treatment-naive participants and with a DTG/3TC control arm is currently enrolling. [28]

A poster at Glasgow 2026 presented more data on the resistance profile of VH-184 and in vitro, VH-184 retained activity against Q148R, R263K and G118R in combination with most other substitutions, which are associated with drug resistance to dolutegravir. [29]

GS-3242 is an INSTI that is very similar to bictegravir, but with a longer half-life that is being developed with a US FDA fast-track designation as oral and injectable formulations. The phase 2 PULSAR 1 and 2 studies using 6-monthly injections paired with lenacapavir in a switch study and in treatment-naive participants respectively and are already enrolling.

A poster at Glasgow reported results from an open-label phase 1b study of oral GS-3242 in people living with HIV. Mean viral reductions at day 11 (following oral doses on day 1 and 2) included -2.4 log copies/mL at the highest 900 mg dose, with a terminal half-life of about 6 days. [30]

ViiV are also developing a 6-monthly formulation of a cabotegravir prodrug called VH-310 that is also in phase 1 studies.

Pipeline capsid inhibitors

Dezecapavir (VH-499), a capsid inhibitor similar to lenacapavir but in development from ViiV, is being studied as a 6-monthly injection in the phase 2b CINERGY treatment-naive study with injectable cabotegravir (dose not specified). Although this study is listed it is not yet enrolling and has an expected end date of mid-2032. [31]

A poster at Glasgow however reported safety and PK results from a phase 1 dose ranging study in 122 HIV-negative participants using SC and IM injectable formulations. No serious AEs or withdrawals were reported, with injection site reactions being the most common. PK of both formulations support 6-monthly injections. [32]

Two other capsid inhibitors in phase 1 stage are GS-3107 and VH-359.

HIV bNAbs

bNAbs are being studied for their potential in treatment, prevention and cure-related studies and have both a direct antiviral effect and vaccine-like immune effect.

Treatment studies, which require baseline sensitivity testing, include Gilead developing 3BNC114 (teropavimab, TAB) and 10-1074 (zinlirvimab, ZAB) given as 6-monthly infusions together with 6-monthly LEN. These studies are now entering phase 3 (DAYBREAK 1 and 2). [33, 34]

ViiV is developing lotivibart (N6LS), also delivered as a 6-monthly infusion, of which results are reported from the phase 2b EMBRACE part 1 study at IAS 2026. [35]

Part 2 of this study using a 6-monthly subcutaneous formulation is already fully enrolled.

One poster at Glasgow reported that lotivibart was associated with modest reductions in chronic immune inflammation in people already suppressed on ART and another was on the positive experiences of health workers administering 6-monthly infusions in the EMBRACE study. [36, 37]

ViiV also has a bispecific bNAb called VH-079 in phase 1 development.

The Glasgow conference included an oral presentation of a phase 2a switch study in 21 people on stable ART using a dual combination of the ibalizumab-like bNAb TMB-365 (VRC07523-LS) and TMB-380. The dual combination was given by infusion every 8 weeks for 25 weeks. [38]

Although two participants discontinued due to rash (on day 7 and 28) this was not reported as a side effect, which is strange. At week 24, 16/21 remained undetectable <50 copies/mL, but with no viral failures.

A related poster from a phase 1 sequential dose escalation study of TMB-365, reported similar mean viral load reduction from baseline of 1.5 log copies/mL at week 2 with both 400 mg and 800 mg doses. Levels returned to roughly 0.5 log lower than baseline by week 5, taking slightly longer than the 800 mg arm although these were small numbers. [39]

Unlike other bNAb studies, baseline sensitivity testing was not needed for this combination.

Other pipeline news from Glasgow

The Glasgow conference also presented new results with several other drugs.

This included an oral presentation on a humanised anti-CD4 antibody (a ‘T-cell engager’) called amtabafusp alfa (ABF). [40]

This small dose-finding study included 54 participants already suppressed on ART. Immunogenicity was measured by the development of anti-drug antibodies (ADAs) which occurred in roughly half the participants, taking about a year to develop.

Albuvirtide is an injectable entry inhibitor being developed in China that is similar to T-20 (enfuvirtide) but is given once-weekly rather than twice-daily.  A poster at Glasgow 2026 reported on a retrospective cohort study of treatment-naive people with advanced HIV (CD4 <200 cells/mm3) who added albuvirtide to B/F/TAF. However, too few details were included (including no participant numbers) that the results are difficult to interpret. [41].

References

Unless stated otherwise, references are to the abstracts for the Glasgow 2026 Conference, published as a supplement to JIAS and available online.
onlinelibrary.wiley.com/doi/full/10.1002/jia2.70211

Full references and URLs are generally only included for studies presented in Glasgow.

  1. Gulick R et al. Novel Strategies and Treatment. Glasgow 2026.
  2. CUARTO study. NCT07650916.
    https://clinicaltrials.gov/study/NCT07650916
  3. Barda et al. HIV Medicine 2025.
  4. Rana et al. LATITUDE study. NEJM 2026.
  5. Chen et al. SUPLA study. CID 2006.
  6. Crown study. NCT06694805.
    https://clinicaltrials.gov/study/NCT06694805.
  7. Gandhi et al. OFID (2024).
  8. Injectable lenacapavir plus CAB-LA: high viral efficacy but ViiV and Gilead restrict further research.
    https://i-base.info/htb/54873
  9. PURPOSE-365. NCT07047716.
    https://clinicaltrials.gov/study/NCT07047716
  10. Hagins et al. AIDS 2026.
    https://pubmed.ncbi.nlm.nih.gov/41056006
  11. Orkin et al. Lancet HIV 2026.
  12. Ruane et al, Glasgow 2026. Poster P062.
  13. D’Antoni ML et al. Bictegravir/Lenacapavir: Baseline and Week 48  Resistance in the ARTISTRY-2 Trial. Glasgow 2026. Poster 048.
  14. Ruane P et al. Characterizing Viraemic Events in the ARTISTRY-1 and ARTISTRY-2 Trials. Glasgow 2026. Poster 062.
  15. Diamond TL. Resistance Analysis at Week 48 of Daily Doravirine/Islatravir (100/0.25mg )Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Blinded Phase3 Study in Adults Initiating Treatment for HIV-1. Glasgow 2026. Poster 060.
  16. Sinclair G et al. Patient-Reported Outcomes With Doravirine/Islatravir (100/0.25mg) Once Daily Versus Bictegravir/Emtricitabine/TenofovirAlafenamide in Virologically Suppressed Adults Living With HIV-1: Phase 3 Results Through Week 96. Glasgow 2026. Poster 063.
  17. Karagiannis A et al. Comparative Efficacy and Safety of Doravirine/Islatravir Versus Contemporary ART Regimens in Virologically Suppressed People Living With HIV-1 at 48 Weeks: A Systematic Review and Network Meta-Analysis. Glasgow 2026. Poster 064.
  18. Parczewski et al. Efficacy and Safety of Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Standard of Care (SOC) Across Demographic and Clinical Subgroups Through Week 48 in the Phase 3 ISLEND-2 Trial. Glasgow 2026. Poster 049.
  19. Rockstroh et al. Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily  Bictegravir/Emtricitabine/TenofovirAlafenamide  (B/F/TAF) in Virologically Suppressed Adults With HIV-1: Week 48 Subgroup Analyses of the Phase3 ISLEND-1 Trial. Glasgow 2026. Poster P050.
  20. Orkin C et al. Understanding Treatment Experiences With Weekly Oral Islatravir/Lenacapavir in the Phase 3 ISLEND-2 Study: Participantand Provider Interviews. Glasgow 2026. Poster P056.
  21. Ramgopal M et al. Quality of Life and Treatment Preference With Weekly ISL/LEN Versus Standard of Care: Week 48 Patient-Reported Outcome Analysis of the Phase 3 ISLEND-2 Study. Glasgow 2026. Poster P057.
  22. Luetkemeyer et al. IAS 2026. Oral late-breaker OAB1405LB.
  23. Pham MM et al. Weekly Ulonivirine Provides a Week of Forgiveness After a Missed Dose. Glasgow 2026. Poster abstract P038.
  24. Gillespie G et al. Phase 1 Study to Investigate the Absorption Metabolism and Excretion of Ulonivirine a Non-Nucleoside Reverse Transcriptase Inhibitor in Adults Without HIV. Glasgow 2026. Poster abstract P265.
  25. Castronova E et al. Phase 1 Results for the Selection of a New Long-Acting Rilpivirine Formulation to Support Dosing Three Times a Year. Glasgow 2026. Oral abstract 039.
  26. Landovitz RJ et al. EXPrESSIVE-11: A Phase 3 Study Evaluating MK-8527 Oral Once Monthly for HIV Pre-Exposure Prophylaxis in Cisgender Men Who Have Sex With Men Transgender Women, Transgender Men and Gender Non-Binary Individuals Who Are at Greater Likelihood of HIV Exposure. Glasgow 2026. Poster abstract P015.
  27. Heffron R et al. EXPrESSIVE-10: A Phase3 Study Evaluating MK-8527 Oral Once Monthly for HIV Pre-Exposure Prophylaxis in Cisgender Women Who Are at Greater Likelihood of HIV Exposure. Glasgow 2026. Poster abstract P017.
  28. NCT07202546.
    https://clinicaltrials.gov/study/NCT07202546
  29. Jeffrey J et al. P043 The Evolution of Integrase Strand Transfer Inhibitors: VH-184, aThird-Generation Inhibitor With an Enhanced Resistance Profile. Glasgow 2026. Poster abstract P043.
  30. Gupta S et al. Antiviral Activity, Pharmacokinetics and Safety of Oral GS-3242 for HIV-1 Treatment. Glasgow 2026. Poster abstract P042.
  31. NCT07816250.
    https://clinicaltrials.gov/study/NCT07816250
  32. Shepherd B et al. Safety, Tolerability and Acceptability of HIV-1 Capsid Inhibitor H4011499 Injectable Formulation. Glasgow 2026, poster abstract P041.
  33. NCT07682961.
    https://clinicaltrials.gov/study/NCT07682961
  34. NCT07683000.
    https://clinicaltrials.gov/study/NCT07683000
  35. Gutner C et al. Participants report positive experiences switching from subcutaneous to intravenous lotivibart (LVB, N6LS, VH3810109) and cabotegravir long-acting injections for HIV-1 treatment in EMBRACE study. IAS 2026. Poster abstract WEPEB097.
    https://programme.aids2026.org/Abstract/Abstract/?abstractid=5995
  36. Keegan et al. Switching From Standard-of-Care Antiretroviral Therapy (SoCART) to Dual Therapy Lotivibart (LVB) Plus Cabotegravir (CAB) Is Associated With a Modest Reduction in Chronic Innate Immune Activation in Virologically Suppressed Adults With HIV. Glasgow 2026. Poster abstract P045.
  37. Gutner C et al. Positive Experiences of Healthcare Staff With Administration ofTwice-Yearly Intravenous Lotivibart for HIV-1 Treatment in the EMBRACE Study. Glasgow 2026. Poster abstract P046.
  38. Markowitz M et al. O31 A24-Week Phase 2a Maintenance Study of TMB-365/TMB-380 q8w in People With Suppressed HIV-1 Infection. Glasgow 2026. Oral abstract O31.
  39. DeJesus E et al. P040 Single-Dose Escalation Study of TMB-365 in People Living With HIV: Safety Pharmacokinetics and Antiviral Activity. Glasgow 2026. Poster 040.
  40. Workowski K et al. Immunogenicity and Associated Safety of Amtabafusp Alfa a Bispecific T-Cell Engager in a Phase1b Study in People With HIV. Glasgow 2026. Oral abstract 33.
  41. Zhu Y et al. Albuvirtide Enhances Immune Recovery in Treatment-Naïve Patients With Advanced HIV Infection Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Retrospective Propensity Score-Matched Cohort Study. Glasgow 2026. Poster 143.